RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oncolys Biopharma - Stock

Oncolys Biopharma P/S 2024

Oncolys Biopharma P/S

11.82

Ticker

4588.T

ISIN

JP3202170001

WKN

A1W94N

As of Jun 23, 2024, Oncolys Biopharma's P/S ratio stood at 11.82, a -93.08% change from the 170.81 P/S ratio recorded in the previous year.

The Oncolys Biopharma P/S history

Oncolys Biopharma Aktienanalyse

What does Oncolys Biopharma do?

Oncolys Biopharma Inc. is a company specialized in the development of innovative medications for the treatment of cancer. The company was founded in 2001 in Tokyo, Japan and has become a key player in the biotechnology industry over the years. The company's business model is based on the development of innovative therapies for cancer patients. It works closely with leading scientists and researchers to advance its research projects, focusing on the discovery and development of new compounds based on the OncoTherad virus. Oncolys Biopharma Inc. offers a wide range of products and services, including cancer medications based on the OncoTherad virus, as well as diagnostic and monitoring tools for hospitals and medical facilities. It has various divisions that encompass research and development, manufacturing, and distribution and marketing of cancer medications and diagnostic systems. The company is committed to expanding its research and development activities to develop new medications for different types of cancer. In addition to cancer medications, Oncolys Biopharma Inc. is also working on developing therapies for other serious illnesses such as viral diseases. The company has a promising pipeline of new medications being tested in various clinical trials. Overall, Oncolys Biopharma Inc. is a key player in the biotechnology industry specializing in the development of innovative therapies for cancer and viral diseases. The company has built an excellent reputation over the years and is committed to continuing its growth and expansion. Oncolys Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Oncolys Biopharma's P/S Ratio

Oncolys Biopharma's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Oncolys Biopharma's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Oncolys Biopharma's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Oncolys Biopharma’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Oncolys Biopharma Stock

What is the price-to-earnings ratio of Oncolys Biopharma?

The price-earnings ratio of Oncolys Biopharma is currently 11.82.

How has the price-earnings ratio of Oncolys Biopharma changed compared to last year?

The price-to-earnings ratio of Oncolys Biopharma has increased by -93.08% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Oncolys Biopharma high compared to other companies?

Yes, the price-to-earnings ratio of Oncolys Biopharma is high compared to other companies.

How does an increase in the price-earnings ratio of Oncolys Biopharma affect the company?

An increase in the price-earnings ratio of Oncolys Biopharma would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Oncolys Biopharma affect the company?

A decrease in the price-earnings ratio of Oncolys Biopharma would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Oncolys Biopharma?

Some factors that influence the price-earnings ratio of Oncolys Biopharma are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Oncolys Biopharma pay?

Over the past 12 months, Oncolys Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncolys Biopharma is expected to pay a dividend of 0 JPY.

What is the dividend yield of Oncolys Biopharma?

The current dividend yield of Oncolys Biopharma is .

When does Oncolys Biopharma pay dividends?

Oncolys Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncolys Biopharma?

Oncolys Biopharma paid dividends every year for the past 0 years.

What is the dividend of Oncolys Biopharma?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncolys Biopharma located?

Oncolys Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncolys Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncolys Biopharma from 6/23/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 6/23/2024.

When did Oncolys Biopharma pay the last dividend?

The last dividend was paid out on 6/23/2024.

What was the dividend of Oncolys Biopharma in the year 2023?

In the year 2023, Oncolys Biopharma distributed 0 JPY as dividends.

In which currency does Oncolys Biopharma pay out the dividend?

The dividends of Oncolys Biopharma are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oncolys Biopharma

Our stock analysis for Oncolys Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncolys Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.